Summary & Key Points
"With the DITRAME and DITRAME+ trials, the PAC-CI program contributed to advancing strategies for reducing mother-to-child transmission of HIV. This work helped to better guide care around several essential dimensions, including maternal treatment, child protection, as well as practices related to pregnancy, childbirth, and breastfeeding."
Did you know?
With DITRAME and DITRAME+, PAC-CI has contributed to advancing the prevention of mother-to-child HIV transmission.
Through the DITRAME and DITRAME+ trials, the PAC-CI Program has contributed to advancing strategies for reducing mother-to-child HIV transmission.
This work has helped to better guide care around several essential dimensions, including maternal treatment, child protection, and practices related to pregnancy, childbirth, and breastfeeding.
By contributing to the production of useful knowledge on this issue, PAC-CI has participated in improving prevention approaches in an area where each advance can durably change the life course of a mother and her child.
The DITRAME and DITRAME+ trials thus illustrate the Program's commitment to the most vulnerable populations, as well as its ability to develop high-impact research for public health.
Christian Kouadio
Clinical Research Associate and Communications Manager at PAC-CI
Contact the author
